dm+d

Unassigned

New Medicines

Active cutaneous lupus erythematosus (CLE), inc. chronic and subacute subtypes +/- systemic manifestations in pts with SLE with active joint and skin manifestations

Information

New molecular entity
Biogen
Biogen

Development and Regulatory status

None
Phase II Clinical Trials
Phase III Clinical Trials

Category

Humanised monoclonal antibody targeting BDCA2 (CLEC4C protein) which is present in cells within the immune system. Interrupts production of interferons (Type I IFN) and other inflammatory cytokines that are increased in pts with SLE. [3,4]
Lupus affects about 1 in 1,000 people in the UK. It is more common in women than in men and typically develops in women aged 20-49. Approximately two-thirds of people with lupus will develop cutaneous lupus erythematosus (CLE).
Active cutaneous lupus erythematosus (CLE), inc. chronic and subacute subtypes +/- systemic manifestations in pts with SLE with active joint and skin manifestations
Subcutaneous